We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Entrada Therapeutics, Inc. (TRDA - Free Report) shares rallied 8.9% in the last trading session to close at $15.79. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.3% gain over the past four weeks.
Entrada Therapeutics’s share price gain can likely be attributed to the growing investor optimism around its product pipeline and upcoming clinical milestones.The company is advancing a broad portfolio of RNA-based therapies targeting neuromuscular diseases like Duchenne muscular dystrophy (DMD) and myotonic dystrophy (DM1), with multiple key data readouts expected in 2026 alongside its partnered DM1 candidate VX-670 with Vertex Pharmaceuticals.Lead candidate ENTR-601-44 is progressing well, with early-stage dosing completed and higher-dose cohorts underway, while ENTR-601-45 has already begun patient dosing in global studies. Additional programs like ENTR-601-50 and ENTR-601-51 are moving toward clinical and regulatory milestones, reflecting steady pipeline expansion.
This company is expected to post quarterly loss of $1.06 per share in its upcoming report, which represents a year-over-year change of -152.4%. Revenues are expected to be $6.36 million, down 69.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Entrada Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TRDA going forward to see if this recent jump can turn into more strength down the road.
Entrada Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Humacyte, Inc. (HUMA - Free Report) , finished the last trading session 8.1% higher at $0.92. HUMA has returned 33.1% over the past month.
Humacyte, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.1. Compared to the company's year-ago EPS, this represents no change. Humacyte, Inc. currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Entrada Therapeutics, Inc. (TRDA - Free Report) shares rallied 8.9% in the last trading session to close at $15.79. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.3% gain over the past four weeks.
Entrada Therapeutics’s share price gain can likely be attributed to the growing investor optimism around its product pipeline and upcoming clinical milestones.The company is advancing a broad portfolio of RNA-based therapies targeting neuromuscular diseases like Duchenne muscular dystrophy (DMD) and myotonic dystrophy (DM1), with multiple key data readouts expected in 2026 alongside its partnered DM1 candidate VX-670 with Vertex Pharmaceuticals.Lead candidate ENTR-601-44 is progressing well, with early-stage dosing completed and higher-dose cohorts underway, while ENTR-601-45 has already begun patient dosing in global studies. Additional programs like ENTR-601-50 and ENTR-601-51 are moving toward clinical and regulatory milestones, reflecting steady pipeline expansion.
This company is expected to post quarterly loss of $1.06 per share in its upcoming report, which represents a year-over-year change of -152.4%. Revenues are expected to be $6.36 million, down 69.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Entrada Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TRDA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Entrada Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Humacyte, Inc. (HUMA - Free Report) , finished the last trading session 8.1% higher at $0.92. HUMA has returned 33.1% over the past month.
Humacyte, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.1. Compared to the company's year-ago EPS, this represents no change. Humacyte, Inc. currently boasts a Zacks Rank of #3 (Hold).